
BIESF
US listing · $1.60B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 5, 2025 | Before the open | — | -0.57 | — |
| Mar 26, 2025 | Before the open | — | -0.09 | — |
| Nov 7, 2024 | Before the open | — | -0.26 | — |
| Aug 6, 2024 | Before the open | — | 0.26 | — |
| May 7, 2024 | Before the open | — | 0.81 | — |
| Mar 28, 2024 | Before the open | — | 1.05 | — |
| May 4, 2022 | After the close | — | -0.14 | — |
| Nov 11, 2021 | Before the open | — | -0.30 | — |
| Aug 11, 2021 | After the close | — | -0.30 | — |
| May 10, 2021 | After the close | 0.00 | -0.13 | — |
| Feb 11, 2021 | Before the open | 0.00 | -0.43 | — |
| Nov 11, 2020 | After the close | — | -0.45 | — |
| Aug 13, 2020 | Time not confirmed | 0.00 | -0.46 | — |
| May 8, 2020 |
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B…
| Before the open |
| 0.00 |
| -0.18 |
| — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.31 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.05 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -0.14 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | 0.08 | — |
| Mar 7, 2019 | Before the open | 0.00 | -0.04 | — |
| Nov 13, 2018 | After the close | 0.00 | -0.18 | — |
| Aug 13, 2018 | After the close | 0.00 | 0.04 | — |
| May 15, 2018 | Before the open | 0.00 | 0.01 | — |
| Feb 27, 2018 | Before the open | 0.00 | -0.25 | — |